TRAX stock forecast, quote, news & analysis
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases... Show more
First Tracks Biotherapeutics (TRAX) Stock Analysis: ANB033 Data Readouts Set the Stage for a Catalyst-Rich 2027
Key Takeaways
- TRAX has moved roughly 7% higher over the trailing 30 days, with shares recently trading near $41 compared with about $38.60 roughly a month earlier.
- The move has been supported by favorable analyst commentary and positive clinical readthroughs from competitors in the celiac disease space.
- First Tracks Biotherapeutics is a clinical-stage immunology company spun off from AnaptysBio in April 2026, led by its CD122 antagonist ANB033.
- Key near-term catalysts include top-line Phase 1b data in celiac disease expected in Q4 2026 and Cohort 2 data in Q1 2027.
- The company has reiterated a cash runway into Q2 2028, reducing near-term financing overhang.
Current Market Snapshot
First Tracks Biotherapeutics has traded in a wide but broadly constructive range over the past month, with the stock moving roughly 7% higher as of late October 2026. The advance has coincided with a steady stream of bullish sell-side commentary and a wave of clinical data from rival programs targeting celiac disease, which investors have interpreted as validation of the mechanism underlying the company's lead asset.
As a recently listed biotech, TRAX remains a high-volatility, event-driven name. Day-to-day trading is heavily influenced by news flow around its pipeline, competitor readouts, and broader sentiment toward the autoimmune and inflammatory disease space. Because the company is pre-revenue, traditional fundamental metrics carry less weight than clinical milestones and the strength of its balance sheet.
First Tracks Biotherapeutics (TRAX) Business Overview and Competitive Position
First Tracks Biotherapeutics is a San Diego-based, clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. The company began trading on the Nasdaq Global Market under the ticker TRAX on April 20, 2026, following its spin-off from AnaptysBio. It launched with approximately $180 million in cash, which management has indicated funds operations into the second quarter of 2028.
The pipeline is anchored by ANB033, a CD122 antagonist in development for celiac disease (CeD) and eosinophilic esophagitis (EoE). The company is also advancing rosnilimab, a pathogenic T cell depleter that completed a Phase 2b trial in rheumatoid arthritis, and ANB101, a BDCA2 modulator that has completed a Phase 1a study in healthy volunteers. Investors follow TRAX primarily for the ANB033 program, which targets a sizable, currently unserved patient population in celiac disease where no approved therapy exists.
Recent Developments Driving TRAX
Several verified developments have shaped investor sentiment around TRAX in recent weeks. In its second-quarter results reported in August 2026, the company announced that the U.S. FDA granted Fast Track designation to ANB033 for the treatment of celiac disease and reaffirmed top-line data from Cohort 1 of its Phase 1b trial for the fourth quarter of 2026, with Cohort 2 data expected in Q1 2027.
Analyst activity has also been supportive. Wells Fargo raised its price target on TRAX to $62 from $55 while maintaining an Overweight rating, citing growing confidence in ANB033 after positive efficacy data from Teva and Argenx in celiac disease. Canaccord Genuity initiated coverage with a Buy rating and a $50 price target, and Barclays has maintained a Buy rating with a $65 target. These actions reflect a view that emerging competitor data strengthens the case for CD122 antagonism and positions ANB033's upcoming readouts as potential differentiation points.
Competitor readthroughs have been a recurring driver. Data from Teva and Argenx has increased investor focus on the celiac disease opportunity and, by extension, on TRAX's near-term catalysts.
Trending AI Robots
For investors seeking a more systematic approach to tracking names like TRAX, Tickeron's Trending AI Robots page offers a curated view of its algorithmic trading tools. Tickeron provides hundreds of AI trading bots that monitor thousands of tickers across different markets, but only the top-performing and most relevant bots are featured in this section. These bots vary in strategy, timeframe, and performance metrics, giving users a range of approaches to explore depending on their objectives. Reviewing the trending selection can be a useful starting point for identifying quantitative signals and strategies that align with a given investing style.
2026 Outlook and What Investors Should Watch
Looking ahead, the single most important catalyst for TRAX is the top-line Cohort 1 data from the Phase 1b ANB033 trial in celiac disease, expected in Q4 2026. Investors will focus on the change in villus height-to-crypt depth ratio and related biomarker measures as evidence of the drug's ability to prevent gluten-induced mucosal injury. Cohort 2 results, anticipated in Q1 2027, will provide additional insight into mucosal healing, followed by Phase 1b EoE data expected in Q3 2027.
Beyond ANB033, the company plans to initiate Phase 2 trials in two additional indications in the first half of 2027, while continuing to evaluate development paths for ANB101 and strategic options for rosnilimab. Competitive data from other IL-15 and CD122 programs, macroeconomic and sector sentiment toward biotech, and the company's progress toward its stated cash runway will also influence the stock. As with all clinical-stage companies, trial outcomes and regulatory decisions remain the dominant sources of risk and opportunity.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TRAX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for TRAX turned positive on October 14, 2026. Looking at past instances where TRAX's MACD turned positive, the stock continued to rise in 1 of 1 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on TRAX as a result. In 10 of 12 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
TRAX moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +17.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRAX advanced for three days, in 27 of 27 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
TRAX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TRAX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. TRAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.054) is normal, around the industry mean (2.988). P/E Ratio (0.000) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology